OverviewSuggest Edit

Myriad Genetics is a molecular diagnostic company which focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The Company offers molecular diagnostic tests, including DNA sequencing tests for hereditary breast, ovarian, colorectal and uterine cancer, a protein quantification test for assessing the disease activity of rheumatoid arthritis, RNA expression tests for assessing the aggressiveness of prostate cancer, diagnosing melanoma, and a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. It also provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries, and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis.
TypePublic
Founded1991
HQSalt Lake City, UT, US
Websitemyriad.com
Employee Ratings4
Overall CultureB-

Latest Updates

Employees (est.) (Jun 2019)2,600(+9%)
Revenue (FY, 2020)$638.6 M(-24%)
Share Price (Feb 2021)$30.4 (+5%)
Cybersecurity ratingCMore

Key People/Management at Myriad Genetics

Bryan Riggsbee

Bryan Riggsbee

Interim President and CEO, Chief Financial Officer
Paul J. Diaz

Paul J. Diaz

President and CEO
Patrick Burke

Patrick Burke

Executive Vice President, Emerging Products
Raymond Francot

Raymond Francot

Executive Vice President, International Operations
Bryan Dechairo

Bryan Dechairo

Officer, Executive Vice President, Development
Clivetty Martinez

Clivetty Martinez

Chief Compliance Officer
Show more

Myriad Genetics Office Locations

Myriad Genetics has offices in Salt Lake City, Austin, South San Francisco, Issy-les-Moulineaux and in 8 other locations
Salt Lake City, UT, US (HQ)
320 Wakara Way
Austin, TX, US
3300 Duval Rd
South San Francisco, CA, US
180 Kimball Way
South San Francisco, CA, US
341 Oyster Point Blvd
Issy-les-Moulineaux, FR
41 Rue Camille Desmoulins
Martinsried, DE
Bunsenstrasse 7
Show all (13)

Myriad Genetics Financials and Metrics

Myriad Genetics Revenue

Myriad Genetics's revenue was reported to be $638.60 m in FY, 2020
USD

Revenue (FY, 2020)

638.6m

Net income (FY, 2020)

(199.6m)

EBIT (FY, 2020)

(231.7m)

Market capitalization (8-Feb-2021)

2.3b

Closing stock price (8-Feb-2021)

30.4

Cash (30-Jun-2020)

163.7m

EV

2.4b
Myriad Genetics's current market capitalization is $2.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

771.4m772.6m851.1m638.6m

Revenue growth, %

4%0%10%

Cost of goods sold

171.2m177.2m201.0m

Gross profit

600.2m595.4m650.1m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

190.2m194.0m193.5m202.3m216.8m216.6m186.3m195.1m

Cost of goods sold

43.0m44.4m44.1m49.7m52.1m48.6m49.7m49.6m

Gross profit

147.2m149.6m149.4m152.6m164.7m168.0m136.6m145.5m

Gross profit Margin, %

77%77%77%75%76%78%73%75%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

102.4m110.9m93.2m163.7m

Accounts Receivable

105.6m98.3m133.9m68.1m

Prepaid Expenses

12.7m9.4m16.6m

Inventories

42.2m34.3m31.4m29.1m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

87.9m88.7m97.4m93.3m90.6m84.9m89.9m81.2m

Accounts Receivable

113.2m121.1m123.7m119.1m116.6m142.6m4.8m118.3m102.5m

Prepaid Expenses

9.5m9.8m10.1m11.5m12.5m11.3m14.0m16.2m

Inventories

38.9m38.2m33.4m35.9m33.3m31.9m28.1m28.1m30.8m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

21.8m131.1m4.6m(199.5m)

Depreciation and Amortization

48.3m54.4m73.0m

Inventories

(1.2m)7.9m8.0m1.6m

Accounts Payable

(3.0m)4.0m1.1m(10.7m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

81.1m113.2m124.6m(700.0k)1.9m8.8m(20.6m)(28.9m)(144.1m)

Depreciation and Amortization

13.2m26.3m39.3m18.3m36.3m54.6m18.2m36.4m54.3m

Inventories

3.3m4.1m8.9m3.5m6.1m7.4m3.1m2.6m

Accounts Payable

400.0k3.0m(2.0m)(8.4m)(300.0k)(8.1m)(9.3m)(11.3m)(2.1m)
USDFY, 2017

Revenue/Employee

321.4k

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.6 x
Show all financial metrics

Myriad Genetics Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Patients Tested to Date

2 m3 m3 m

Products

11

Publications to Date

1 k

Countries

143
Show all operating metrics

Myriad Genetics Acquisitions / Subsidiaries

Company NameDateDeal Size
Myriad Women’s HealthMay 29, 2018$408.60 m
Myriad NeuroscienceAugust 03, 2016$351.60 m
Sividon DiagnosticsMay 31, 2016$56 m
Privatklinik Dr. Robert SchindlbeckFebruary 27, 2015$20.10 m
Crescendo BioscienceFebruary 04, 2014$270 m
Rules-Based MedicineApril 27, 2011$80 m
Javelin PharmaceuticalsDecember 18, 2009$95 m
NaturNorth TechnologiesApril 10, 2008
AssureRx Canada, Ltd
Assurex Health, Inc.
Show more

Myriad Genetics Revenue Breakdown

Embed Graph

Myriad Genetics revenue breakdown by business segment: 7.2% from Pharmaceutical and Clinical Services and 92.8% from Molecular Diagnostic Testing

Myriad Genetics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

SecurityScorecard logo

Myriad Genetics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Myriad Genetics Online and Social Media Presence

Embed Graph

Myriad Genetics Company Culture

  • Overall Culture

    B-

    70/100

  • CEO Rating

    D

    61/100

  • Compensation

    B

    74/100

Learn more on Comparably

Myriad Genetics News and Updates

Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis

SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- To help more patients with rheumatoid arthritis (RA), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today launched the new Vectra® Cardiovascular Risk assessment that can predict the risk for cardiovascul…

Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan

Patients with Prostate or Pancreatic Cancer to Benefit from Treatment with Lynparza

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Myriad Genetics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Myriad Genetics, Inc. (NASDAQ: MYGN). If you...

Myriad Genetics Forms Strategic Partnership with Illumina in Oncology

Note: Paul Diaz, President & CEO of Myriad Genetics will speak today at the 39th Annual JP Morgan Healthcare Conference at 2:50 p.m. EST accessible via a live audio webcast at the following direct link or through the investor section of Myriad’s website at www.myriad.com.

Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®

SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice® Diagnostic System, which helps determine if women with ovarian canc…

Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare Conference

Mr. Diaz will focus on key opportunities to fulfill the company’s mission of improving patient lives by unlocking the power of precision medicine and helping healthcare providers and payers prevent, diagnose and treat disease through the company’s genetic insights. The presentation will be available…
Show more

Myriad Genetics Blogs

Celebrating Diversity at Myriad Genetics

Here at Myriad Genetics, we take every opportunity to rejoice in our team’s diversity. During Black History Month, we’ve been doing… The post Celebrating Diversity at Myriad Genetics appeared first on Myriad Genetics, Inc..

February Is National Cancer Prevention Month

In honor of National Cancer Prevention Month, we wanted to raise awareness of some actions you can take right now to… The post February Is National Cancer Prevention Month appeared first on Myriad Genetics, Inc..

New Publication Demonstrates Value of Combining Clinical and Genetic Risk Models for More Accurate Breast Cancer Risk Prediction

By Thomas Slavin, M.D., Senior Vice President of Medical Affairs, Oncology A new, peer-reviewed paper published in JCO Precision Oncology shows… The post New Publication Demonstrates Value of Combining Clinical and Genetic Risk Models for More Accurate Breast Cancer Risk Prediction appeared first on…

How Genetic Testing Saved My Life

It was 6 years ago that I learned I was BRCA2+. The Myriad myRisk® test was encouraged by my OB/GYN based… The post How Genetic Testing Saved My Life appeared first on Myriad Genetics, Inc..

Myriad Genetics Recognizes Three Distinguished Directors for 55 Years of Combined Board Service

At the December meeting of its Board of Directors, Myriad Genetics recognized the meaningful contributions of three retiring board members —… The post Myriad Genetics Recognizes Three Distinguished Directors for 55 Years of Combined Board Service appeared first on Myriad Genetics, Inc..

From Genetic Counselor to President: A Personal Chat with Nicole Lambert, President, Myriad Genetic Laboratories, Sharing the Passion for Improving Lives

Today, on Genetic Counselors Awareness Day, we at Myriad Genetics want to recognize and show appreciation to all the genetic counselors who dedicate themselves… The post From Genetic Counselor to President: A Personal Chat with Nicole Lambert, President, Myriad Genetic Laboratories, Sharing the Pass…
Show more

Myriad Genetics Frequently Asked Questions

  • When was Myriad Genetics founded?

    Myriad Genetics was founded in 1991.

  • Who are Myriad Genetics key executives?

    Myriad Genetics's key executives are Bryan Riggsbee, Paul J. Diaz and Patrick Burke.

  • How many employees does Myriad Genetics have?

    Myriad Genetics has 2,600 employees.

  • What is Myriad Genetics revenue?

    Latest Myriad Genetics annual revenue is $638.6 m.

  • What is Myriad Genetics revenue per employee?

    Latest Myriad Genetics revenue per employee is $245.6 k.

  • Who are Myriad Genetics competitors?

    Competitors of Myriad Genetics include Progenity, Foundation Medicine and Genomic Health.

  • Where is Myriad Genetics headquarters?

    Myriad Genetics headquarters is located at 320 Wakara Way, Salt Lake City.

  • Where are Myriad Genetics offices?

    Myriad Genetics has offices in Salt Lake City, Austin, South San Francisco, Issy-les-Moulineaux and in 8 other locations.

  • How many offices does Myriad Genetics have?

    Myriad Genetics has 13 offices.